BACKGROUND: The use of mesenchymal stem cells (MSCs) to treat osteochondral defects caused by sports injuries or disease is of particular interest. However, there is a lack of studies in large-animal models examining the benefits of chondrogenic predifferentiation in vitro for repair of chronic osteochondral defects. HYPOTHESIS: Chondrogenic in vitro predifferentiation of autologous MSCs embedded in a collagen I hydrogel currently in clinical trial use for matrix-associated autologous chondrocyte transplantation facilitates the regeneration of a chronic osteochondral defect in an ovine stifle joint. STUDY DESIGN: Controlled laboratory study. METHODS: The optimal predifferentiation period of ovine MSCs within the type I collagen hydrogel in vitro was defined by assessment of several cellular and molecular biological parameters. For the animal study, osteochondral lesions (diameter 7 mm) were created at the medial femoral condyles of the hind legs in 10 merino sheep. To achieve a chronic defect model, implantation of the ovine MSCs/hydrogel constructs was not performed until 6 weeks after defect creation. The 40 defects were divided into 4 treatment groups: (1) chondrogenically predifferentiated ovine MSC/hydrogel constructs (preMSC-gels), (2) undifferentiated ovine MSC/hydrogel constructs (unMSC-gels), (3) cell-free collagen hydrogels (CF-gels), and (4) untreated controls (UCs). Evaluation followed after 6 months. RESULTS: With regard to proteoglycan content, cell count, gel contraction, apoptosis, compressive properties, and progress of chondrogenic differentiation, a differentiation period of 14 days in vitro was considered optimal. After 6 months in vivo, the defects treated with preMSC-gels showed significantly better histologic scores with morphologic characteristics of hyaline cartilage such as columnarization and presence of collagen type II. CONCLUSION: Matrix-associated autologous chondrocyte transplantation with predifferentiated MSCs may be a promising approach for repair of focal, chronic osteochondral defects. CLINICAL RELEVANCE: The results suggest an encouraging method for future treatment of focal osteochondral defects to prevent progression to osteoarthritis.
BACKGROUND: The use of mesenchymal stem cells (MSCs) to treat osteochondral defects caused by sports injuries or disease is of particular interest. However, there is a lack of studies in large-animal models examining the benefits of chondrogenic predifferentiation in vitro for repair of chronic osteochondral defects. HYPOTHESIS: Chondrogenic in vitro predifferentiation of autologous MSCs embedded in a collagen I hydrogel currently in clinical trial use for matrix-associated autologous chondrocyte transplantation facilitates the regeneration of a chronic osteochondral defect in an ovine stifle joint. STUDY DESIGN: Controlled laboratory study. METHODS: The optimal predifferentiation period of ovine MSCs within the type I collagen hydrogel in vitro was defined by assessment of several cellular and molecular biological parameters. For the animal study, osteochondral lesions (diameter 7 mm) were created at the medial femoral condyles of the hind legs in 10 merino sheep. To achieve a chronic defect model, implantation of the ovine MSCs/hydrogel constructs was not performed until 6 weeks after defect creation. The 40 defects were divided into 4 treatment groups: (1) chondrogenically predifferentiated ovine MSC/hydrogel constructs (preMSC-gels), (2) undifferentiated ovine MSC/hydrogel constructs (unMSC-gels), (3) cell-free collagen hydrogels (CF-gels), and (4) untreated controls (UCs). Evaluation followed after 6 months. RESULTS: With regard to proteoglycan content, cell count, gel contraction, apoptosis, compressive properties, and progress of chondrogenic differentiation, a differentiation period of 14 days in vitro was considered optimal. After 6 months in vivo, the defects treated with preMSC-gels showed significantly better histologic scores with morphologic characteristics of hyaline cartilage such as columnarization and presence of collagen type II. CONCLUSION: Matrix-associated autologous chondrocyte transplantation with predifferentiated MSCs may be a promising approach for repair of focal, chronic osteochondral defects. CLINICAL RELEVANCE: The results suggest an encouraging method for future treatment of focal osteochondral defects to prevent progression to osteoarthritis.
Authors: Jennifer K Lee; Donald J Responte; Derek D Cissell; Jerry C Hu; Jan A Nolta; Kyriacos A Athanasiou Journal: Crit Rev Biotechnol Date: 2013-10-01 Impact factor: 8.429
Authors: Zheng Yang; Yu Zou; Xi Min Guo; Hwee San Tan; Vinitha Denslin; Chen Hua Yeow; Xia Fei Ren; Tong Ming Liu; James Hp Hui; Eng Hin Lee Journal: Stem Cells Dev Date: 2012-01-17 Impact factor: 3.272
Authors: Maria Skog; Virpi Muhonen; Johanna Nystedt; Roberto Narcisi; Leena-Stiina Kontturi; Arto Urtti; Matti Korhonen; Gerjo J V M van Osch; Ilkka Kiviranta Journal: Cytotechnology Date: 2014-04-10 Impact factor: 2.058
Authors: Troy D Bornes; Nadr M Jomha; Aillette Mulet-Sierra; Adetola B Adesida Journal: Tissue Eng Part C Methods Date: 2016-01-18 Impact factor: 3.056
Authors: J Lam; S Lu; E J Lee; J E Trachtenberg; V V Meretoja; R L Dahlin; J J J P van den Beucken; Y Tabata; M E Wong; J A Jansen; A G Mikos; F K Kasper Journal: Osteoarthritis Cartilage Date: 2014-07-04 Impact factor: 6.576